

THE TRANSFORMATION FROM CRPC INTO BONE-MIGRATED PROSTATE CANCER

A Multidisciplinary Case-Based Approach to the Management of Prostate Cancer in the Bone



ESMO 2016 Industry Satellite Symposium

THE TRANSFORMATION FROM CRPC INTO BONE-MIGRATED PROSTATE CANCER

A Multidisciplinary Case-Based Approach to the Management of Prostate Cancer in the Bone

INVITATION

Friday, 7 October 2016 18:00 to 20:00

Bella Exhibition and Convention Center / Copenhagen / Denmark

Bern Auditorium

Meal Will Be Provided



DEAR COLLEAGUES,

It gives me great pleasure to invite you to a Bayer-sponsored Satellite Symposium on Friday, the 7th of October, from 18:00 to 20:00. This program will allow clinicians to discuss and critique the latest strategies for optimizing treatment outcomes in metastatic castrate-resistant prostate cancer (mCRPC). Our understanding of the nature of metastatic prostate cancer has dramatically advanced, and translational research has furthered the management potential of mCRPC in the past decade, with new therapeutic options becoming available.

Although several agents have demonstrated an overall survival benefit, considerable controversy remains regarding unresolved aspects of treatment. This symposium will seek to address controversies surrounding the nature of bone-migrated prostate cancer, the interpretation of biomarkers when evaluating treatment efficacy or failure, ideal imaging protocols, and the optimal sequencing of therapies. It will give attendees a robust opportunity to learn from relevant clinical scenarios while providing a platform to discuss challenging clinical situations with our panel of international experts.

Furthermore, the symposium will provide the audience with a forum to share real-world clinical experiences and challenges, presenting the opportunity to confer about best practices through an interactive forum with the faculty. By actively participating in this expert forum, attendees will provide insight on how to best apply currently available evidence in order to optimize long-term survival outcomes.

I am confident that this program will help advance the care of mCRPC patients by encouraging a dialogue about key issues and challenging aspects of treatment. I anticipate that you will find this symposium of value and look forward to welcoming you.

Yours sincerely,

Chal

Dr. Christopher Parker Honorary Consultant in Clinical Oncology Royal Marsden Hospital, Sutton Senior Lecturer in Prostate Cancer Translational Research Institute of Cancer Research, Sutton

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

- Interpret recent advancements in the understanding of the mechanistic pathways and virulence of prostate cancer once it has migrated to the bone
- Describe radiographic findings and novel scanning modalities for disease monitoring
- Elucidate the clinical implications of bone-migrated prostate cancer as it relates to prognostic and diagnostic biomarkers
- Define the current optimal sequencing paradigm of mCRPC treatment via a multidisciplinary approach and reveal additional novel outcomes research that may influence future sequencing of available agents

AGENDA

Time	Title	Speaker
18:00 – 18:10	Welcome and Introduction	Dr. Christopher Parker Royal Marsden Hospital, UK
18:10 – 18:40	The Evolution of Bone-Migrated Prostate Cancer Recent advancements in the understanding of prostate cancer in the bone	Dr. Neal Shore Carolina Urologic Research Center, USA
18:40 – 18:50	Bone-Migrated Prostate Cancer: Radiographic Perspectives Novel scanning modalities in disease monitoring	Dr. Francis Sundram Southampton General Hospital, UK
18:50 – 19:00	Panel Discussion The clinical implications of bone-migrated prostate cancer	All faculty
19:00 – 19:50	Case Reviews – A Multidisciplinary Approach Amongst Urology, Medical Oncology, and Nuclear Medicine Optimizing sequencing strategies Disease monitoring and clinical evaluation strategies	All faculty
19:50 – 20:00	Closing Remarks & Key Concepts	Dr. Christopher Parker Royal Marsden Hospital UK

© Bayer HealthCare Pharmaceuticals Inc.